Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) EBITDA (2016 - 2025)

Fate Therapeutics (FATE) has disclosed EBITDA for 14 consecutive years, with -$32.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 38.52% year-over-year to -$32.4 million, compared with a TTM value of -$136.5 million through Dec 2025, up 26.63%, and an annual FY2025 reading of -$136.5 million, up 26.63% over the prior year.
  • EBITDA was -$32.4 million for Q4 2025 at Fate Therapeutics, down from -$32.2 million in the prior quarter.
  • Across five years, EBITDA topped out at -$17.7 million in Q1 2023 and bottomed at -$83.4 million in Q3 2022.
  • Average EBITDA over 5 years is -$48.9 million, with a median of -$45.9 million recorded in 2021.
  • The sharpest move saw EBITDA skyrocketed 73.93% in 2023, then crashed 172.81% in 2024.
  • Year by year, EBITDA stood at -$69.3 million in 2021, then grew by 20.7% to -$55.0 million in 2022, then rose by 20.66% to -$43.6 million in 2023, then decreased by 20.9% to -$52.7 million in 2024, then soared by 38.52% to -$32.4 million in 2025.
  • Business Quant data shows EBITDA for FATE at -$32.4 million in Q4 2025, -$32.2 million in Q3 2025, and -$34.2 million in Q2 2025.